open access

Vol 14, No 4 (2017)
Review paper
Get Citation

Aripiprazole 15 mg/day — activation and less side effects. Clinical cases

Piotr Gałecki
Psychiatria 2017;14(4):197-203.

open access

Vol 14, No 4 (2017)
Prace poglądowe - nadesłane

Abstract

Aripiprazole is one of the commercially available formulas that ensure therapeutic efficacy in the treatment of schizophrenia with a relatively small number of unwanted symptoms. Owing to the relief of positive and negative symptoms of schizophrenia, and a reduced risk of causing extrapyramidal symptoms, it is applied as the first-line drug in the treatment of episodes of this particular disease. Aripiprazole is also effective in the case of pharmacotherapy changes, in the long-lasting treatment of schizophrenic psychoses and other groups of mental disorders. This work presents clinical cases of patients treated using aripiprazole, with emphasis placed on the indications for application of this formula and a description of the mechanisms of its action.

Abstract

Aripiprazole is one of the commercially available formulas that ensure therapeutic efficacy in the treatment of schizophrenia with a relatively small number of unwanted symptoms. Owing to the relief of positive and negative symptoms of schizophrenia, and a reduced risk of causing extrapyramidal symptoms, it is applied as the first-line drug in the treatment of episodes of this particular disease. Aripiprazole is also effective in the case of pharmacotherapy changes, in the long-lasting treatment of schizophrenic psychoses and other groups of mental disorders. This work presents clinical cases of patients treated using aripiprazole, with emphasis placed on the indications for application of this formula and a description of the mechanisms of its action.

Get Citation

Keywords

aripiprazole, treatment, schizophrenia

About this article
Title

Aripiprazole 15 mg/day — activation and less side effects. Clinical cases

Journal

Psychiatria (Psychiatry)

Issue

Vol 14, No 4 (2017)

Article type

Review paper

Pages

197-203

Bibliographic record

Psychiatria 2017;14(4):197-203.

Keywords

aripiprazole
treatment
schizophrenia

Authors

Piotr Gałecki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl